For reference, we’ve compiled a list of all the links on the site, plus a few more:

INSPIRATION

EVENTS

September 30, 2023: Gustavo Santaolalla, Two-Time Oscar Winning Film Composer, Performs a Unique Solo Presentation for Aveni Foundation

July 22, 2022: Celebrating the 200th Mendel’s Anniversary

September 16, 2020: Dr Gordon at ASGCT Covid-19 Symposium

November 18, 2019: James B Finn Memorial (flyer)

November 14, 2019: Artists for Aveni Foundation (tickets)

November 14, 2019: Artists for Aveni Foundation (flyer)

@artistsforaveni

ARTICLES

ASGCT 2024: Tumor Agnostic DeltaRex-G+ Gene Therapy Demonstrates Activity in Breast, Pancreatic, Sarcoma Cancers

Cancer Therapy Advisor Commentary: The Revival of a Forgotten Cancer Gene Therapy with Off-the-Shelf Potential

Press Releases

Sarcoma Oncology Center Leverages BostonGene’s AI-driven Molecular and Immune Profiling Platform to Identify Novel Treatment Options for Patients with Advanced Cancers

Aveni Foundation Publishes "From Mendel to Gene Therapy" Mapping the History of Genetic Medicine

AI Analaysis Shows Enhanced CCNG1 Expression in Sarcoma: A Novel Biomarker for DeltaRex-G CCNG1 Inhibitor Therapy

BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer and Sarcoma

DeltaRex-G Expands USFDA Authorized Access to Breast Cancer, Pancreas Cancer, Osteosarcoma, and Soft Tissue Sarcoma

Gustavo Santaolalla, Two-Time Oscar Winning Film Composer, Performs a Unique Solo Presentation for Aveni Foundation

UK Philanthropists Simone and Paul Commins Donated GBP 100,000 for DeltaRex-G Cancer Research

DeltaRex-G as Front-line Treatment for Early-stage Breast Cancer Shows Heartening Results

DeltaRex-G gains FDA Authorization as Adjuvant Therapy for Early-stage Triple Negative Metaplastic Breast Cancer

DeltaRex-G Gains FDA Authorization as First-Line Therapy for Early-Stage Triple Receptor Positive Breast Cancer

DeltaRex-G Gains Emergency Use Authorization for Severe COVID-19

Tumor Markers for DeltaRex-G, the Safer Checkpoint Inhibitor for Sarcoma

Corona Study Using DeltaRex-G for COVID-19

DeltaRex-G Impedes Tumor Growth in Stage 4 Chemotherapy-Resistant Bone Cancer

CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19

DeltaRex-G Gene Therapy for Chemotherapy-Induced Leukemia

US FDA Expanded Access for DeltaRex-G

DeltaRex-G induces 10-year remission in a Stage IV pancreatic cancer patient - A cure for pancreas cancer in 2019?

Exploiting the oncogenic drivers of the CCNG1 pathway

Papers

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer

Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy

Noteworthy clinical case studies in cancer gene therapy: Tumor-targeted Rexin-G advances as an efficacious anti-cancer agent

Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study of intravenous Rexin-G and Reximmune-C for chemotherapy-resistant cancers.

Rexin‐G®, a tumor‐targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Fr Aveni

In loving memory of Rev. Fr. Joseph Aveni, RCJ on the occasion of his 70th Priestly Anniversary - July 15, 1945.

Fr. Aveni Stampita (pdf)

10-year Survivors (see News & Notes for more)

Ruth Oliver (10 year pancreas cancer survivor)

Rosario Lazo’s Full Testimony (pdf)

Mond Florida (10 year osteosarcoma survivor)

Mond Florida’s Full Testimony (pdf)

Kendra Krause (10 year osteosarcoma survivor)

Jackie Pancari (11 year breast cancer survivor)

Artist-in-Residence: Jackie Pancari

CANCER STATS

World Health Organization: Cancer Fact Sheet

American Cancer Society: Global Cancer Facts & Figures